A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
Not specified
Study Completion Date
October 31, 1992
Conditions
HIV Infections
Interventions
DRUG
Ampligen
Trial Locations (1)
Unknown
Univ of Pittsburgh Med School, Pittsburgh
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000713 - A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects | Biotech Hunter | Biotech Hunter